Cadrenal Therapeutics, Inc. provided a corporate update on November 7, 2024, coinciding with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. The company highlighted building momentum from achieving several critical milestones towards initiating a pivotal clinical trial for tecarfarin.
Quang X. Pham, CEO, stated that nearly $10 million was efficiently raised in recent weeks, bolstering funds for operational and clinical development needs. This financing supports the company's strategic plan moving into 2025.
The company is also progressing its dialogue with the FDA and Abbott, and advancing manufacturing efforts with its CDMO for the Phase 3 trial. Tecarfarin is noted as the only anticoagulant in development worldwide for patients with implanted cardiac devices and other rare cardiovascular conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.